Raymond James Financial’s Medifast MED Stock Holding History

Raymond James Financial’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-307	Closed	-$4.31K	–	6004
2025 Q2	$4.31K	Buy	+307	New	+$4.03K	﹤0.01%	6212

Other funds holding MED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Lido Advisors Los Angeles, California $32.7B AUM 19.2% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Raymond James Financial's MED Position: Q3 2025 in Review

Raymond James Financial sold out of Medifast (MED) in Q3 2025, closing a stake of 307 shares — an estimated $4.31K sold.

Raymond James Financial first reported a position in MED in Q2 2025 and held it in 1 quarter. The position peaked at $4.31K in Q2 2025. 123 funds tracked by Wall St. Rank hold MED as of Q3 2025.

Raymond James Financial reported no remaining Medifast position as of Q3 2025 after selling out during the quarter.
Raymond James Financial sold 307 Medifast shares in Q3 2025, an estimated $4.31K.
Raymond James Financial first reported a position in Medifast in Q2 2025 and held it in 1 quarter.
Raymond James Financial's Medifast position peaked at $4.31K in Q2 2025.
123 funds tracked by Wall St. Rank held Medifast as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.